Sign in
CompletedPhase 1

Oral Buprenorphine as a Novel Low-dose Induction Strategy for Opioid Use Disorder

Key facts

Who runs it
Brigham and Women's Hospital
Where
Boston, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 1
People taking part
18 people enrolled
Started
4 Jun 2024
Ended
1 Oct 2025
Type of study
Interventional, 3 groups
Treatments tested
  • Buprenorphine
Record updated
23 October 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • English-speaking adults aged 18 and above
  • In good physical health as determined by routine medical screening consisting of a complete physical exam, safety labs and EKG
  • Baseline vital signs with HR between 60 and 100, SBP between 90 and 160mmHg, and respiratory rate between 12 and 20 breaths per minute
  • Prior personal history of opioid use, therapeutic or non-therapeutic in past the 12 months

Who cannot take part

  • Receiving treatment with opioid analgesic in last 60 days, or anticipate requiring opioids during the proposed trial, or up to 30 days after the trial completion
  • Receiving medications that are strong or moderate CYP34A inducers or inhibitors (including but not limited to ketoconazole, itraconazole, clarithromycin, fluconazole, erythromycin), in the past 30 days
  • DSM-5 diagnosis of any substance use disorder excluding tobacco
  • History of chronic pain
  • Psychotic disorder, active suicidality or homicidally, or any psychiatric condition that impair ability to provide informed consent
  • History of hypersensitivity or allergy to buprenorphine or naltrexone
  • Presence of any alcohol, cannabis, opioids (including methadone, buprenorphine) or any other illicit substances on urine toxicology at any study visit, including cocaine, amphetamines, and benzodiazepines
  • Baseline PHQ-9 or GAD7 > 10 (i.e. moderate depression/anxiety)
  • Pregnant or breastfeeding
  • Liver function test greater than 3 times upper normal limit

Where in United States

  • Brigham and Women's HospitalBoston, United States

About the trial

What the trial wants to find out

This is a human laboratory-based, randomized, cross-over study in which buprenorphine will be administered to healthy volunteers (n=22) in 3 separate inpatient 2-night visits, at least 1 week apart. At each visit, the participant will receive a single dose buprenorphine, either 0.15mg IV, 8mg PO, or 16mg PO. The order for the first dose administered will be fixed to the IV dose, and the subsequent doses will be randomized and counterbalanced to 8mg or 16mg PO. Participants will be given naltrexone to produce opioid blockade to eliminate the risk for opioid dependence in individuals without OUD. Timed blood samples will be collected up to 24 hours.

The 3 groups in the trial

  • 8mg PO buprenorphineTreatment being tested

    After the open-label period, the participant will receive 8mg PO, then 16mg PO will be administered in the following visit.

    Treatment: Buprenorphine

  • 16mg PO buprenorphineTreatment being tested

    After the open-label period, the participant will receive 16mg PO, then 8mg PO will be administered in the following visit.

    Treatment: Buprenorphine

  • 0.15mg IV DoseTreatment being tested

    The first dose administered will be fixed to an open-label 0.15mg IV dose.

    Treatment: Buprenorphine

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Oral Buprenorphine as a Novel Low-Dose Induction Strategy for Individuals With Opioid Use Disorder
Record updated
23 October 2025